Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mazin Foteh

Vascular Surgery Austin, TX Medical Doctor

NPI 1811191794 CMS profile 355039

1010 W 40Th St, Austin, TX 78756

Open in the dashboard

General payments

$1,647,418

1,301 records reported · program years 2019–2025

Research payments

$53,614

Paid to them · 7 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$831,986 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Mazin Foteh of Austin, TX is reported in the CMS Open Payments database as having received $1,647,418 across 1,301 general payments and $53,614 in research payments paid to them. Separately, studies naming them as principal investigator received $831,986 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $198,318 147
2024 General $203,759 144
2023 General $233,815 166
2022 General $317,809 244
2021 General $315,716 270
2021 Research $39,164 3
2020 General $226,135 159
2020 Research $1,600 1
2019 General $151,865 171
2019 Research $12,850 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mazin Foteh
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Mazin Foteh were reported at $198,318. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Mazin Foteh Vascular Surgery median Middle half National median
2019 $151,865 $796 $226–$2,363 $163
2020 $226,135 $348 $118–$1,110 $114
2021 $315,716 $471 $158–$1,421 $132
2022 $317,809 $725 $222–$2,183 $149
2023 $233,815 $836 $257–$2,440 $160
2024 $203,759 $909 $252–$2,619 $164
2025 $198,318 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bolton Medical Inc $660,184 565 payments
  2. Shockwave Medical, Inc $398,794 170 payments
  3. Penumbra, Inc. $224,498 118 payments
  4. Terumo Medical Corporation $120,699 117 payments
  5. Cardiovascular Systems Inc. $78,860 59 payments
  6. Silk Road Medical, Inc. $75,195 68 payments
  7. W. L. Gore & Associates, Inc. $43,676 56 payments
  8. Cagent Vascular LLC $13,800 6 payments
  9. Veryan Medical Incorporated $7,170 4 payments
  10. Medtronic, Inc. $5,097 12 payments
  11. Other $19,444 126 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $695,788 248 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $278,550 80 payments
  3. Education $240,785 116 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $217,530 75 payments
  5. Travel and Lodging $78,175 171 payments
  6. Honoraria $56,060 27 payments
  7. Food and Beverage $42,986 573 payments
  8. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $37,545 11 payments
Products named General payments · program years 2019–2025
  1. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $209,389 78 payments
  2. TREO ABDOMINAL STENT-GRAFT SYSTEM $202,094 188 payments
  3. Grafts $142,330 125 payments
  4. Relay Grafts $134,556 164 payments
  5. RUBY Coil $129,442 51 payments
  6. RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM $121,293 59 payments
  7. Vascular Lithotripsy Lithoplasty $98,649 49 payments
  8. Vascular Lithotripsy Lithoplasty $60,932 21 payments
  9. ENROUTE 0.014 Guidewire $54,291 57 payments
  10. ENROUTE Transcarotid Stent System $54,291 57 payments
  11. Other $830,827 742 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Veryan Medical Incorporated $39,164 3 payments
  2. Terumo Medical Corporation $14,450 4 payments

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

24

Median for Vascular Surgery: 122

Drug cost

$159

Median for Vascular Surgery: $14,135

Branded share of claims

100%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 24 $159

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 149 billing codes

Paid by Medicare

$162,284

Medicare's payments for the services billed

Medicare patients

229

Average age 75

Services billed

795

86 women, 143 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 70%
Chronic kidney disease 60%
Diabetes 53%
Arthritis 51%
Heart failure 44%
Atrial fibrillation 41%
COPD 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

1,308 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record